Grifols (NASDAQ:GRFS) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Grifols from “hold” to “buy.” Other analyst views are mixed, with MarketBeat reporting an average “Reduce” rating and a $9 price target.
• Grifols shares were down 1.3% and opened at $8.69; the stock’s 52-week range is $6.96 to $9.77.
• Several institutional investors, including Flat Footed LLC and Quantinno Capital Management, increased their Grifols holdings.

Grifols (NASDAQ:GRFS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

GRFS has been the topic of several other research reports. JPMorgan Chase & Co. cut their price objective on shares of Grifols from $10.00 to $9.00 and set a "neutral" rating on the stock in a research report on Monday, October 26th. Weiss Ratings raised shares of Grifols from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, November 4th. Finally, Zacks Research lowered shares of Grifols from a "hold" rating to a "strong sell" rating in a research note on Tuesday, November 3rd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Grifols has an average rating of "Reduce" and an average target price of $9.00.

Grifols Trading Down 1.3%

Shares of NASDAQ GRFS opened at $8.69 on Friday. The business has a 50 day simple moving average of $7.75 and a 200 day simple moving average of $7.99. Grifols has a 52 week low of $6.96 and a 52 week high of $9.77. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.33 and a quick ratio of 0.82.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Flat Footed LLC boosted its position in Grifols by 26.5% during the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company's stock worth $11,007,000 after purchasing an additional 287,867 shares during the period. Tidal Investments LLC raised its position in shares of Grifols by 9.8% in the second quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company's stock valued at $8,730,000 after purchasing an additional 109,612 shares during the period. Royal Bank of Canada raised its position in shares of Grifols by 15.4% in the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company's stock valued at $6,301,000 after purchasing an additional 104,850 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in shares of Grifols by 13.8% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company's stock valued at $4,193,000 after purchasing an additional 72,037 shares during the period. Finally, Quantinno Capital Management LP lifted its stake in shares of Grifols by 42.0% in the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company's stock worth $2,829,000 after buying an additional 104,418 shares during the last quarter.

About Grifols

Grifols is a global healthcare company headquartered in Barcelona, Spain, focused on developing and producing plasma-derived medicines and other healthcare products. Founded in 1909, the company has expanded from its origins in laboratory services into a business spanning plasma collection, biopharmaceuticals, diagnostics and hospital solutions. Its biopharmaceutical business collects and processes human plasma to make medicines, including immunoglobulins, albumin and coagulation factors. Grifols also supplies diagnostic products and services for transfusion medicine and offers products used in hospitals and clinical laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.